Fulcrum Therapeutics(FULC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The 20 mg cohort of pociredir showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [9][15] - Total hemoglobin increased by more than 1 g/dL after 12 weeks of treatment [9][20] - The safety profile of pociredir at the 20 mg dose remains generally well-tolerated, with no treatment-related serious adverse events reported [21][80] Business Line Data and Key Metrics Changes - In the 20 mg cohort, 58% of patients achieved HbF levels at or above 20%, which is associated with clinically meaningful protection [9][15] - The cohort demonstrated a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin, indicating reduced hemolysis [18] - A 42% drop in reticulocytes was observed, reflecting decreased bone marrow stress due to reduced hemolysis [19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with current options limited primarily to hydroxyurea [25][86] - The global sickle cell disease population is estimated at 7.7 million, with a substantial number in Sub-Saharan Africa [90] Company Strategy and Development Direction - The company plans to initiate a potential registration-enabling trial in the second half of 2026, pending feedback from the FDA [31] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance [31] - The company aims to maintain a competitive edge in the market, believing it has a two-year head start over competitors [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce vaso-occlusive crises and hemolytic anemia in sickle cell disease patients [25][26] - The management highlighted the importance of advancing into a registration-enabling study due to the robust data generated [51][82] - There is a strong belief that if results are replicated in late-phase clinical trials, pociredir could serve as a first-line therapy for sickle cell disease [29] Other Important Information - The 20 mg cohort had no transfusions during the treatment period, contrasting with the 12 mg cohort [20] - The study design included a high degree of disease severity among participants, which is critical for understanding treatment efficacy [12] Q&A Session Summary Question: Can you provide insight into the VOC data and when they occurred? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [35] Question: How well does the 20 mg cohort represent the broader sickle cell patient population? - The 20 mg cohort is believed to represent a middle slice of the global population, with more heterogeneity observed in patients from Nigeria compared to South Africa [36][38] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show changes over time as HbF levels increase [41][43] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data and the biological relationship between HbF levels and clinical outcomes with the FDA [51][52] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment showing sustained effects, and many patients still experiencing severe events [86]